Clinical Trial Update: HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of HuMax-IL8 for patients with advanced malignant solid tumors has completed, providing early safety and tolerability data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• HuMax-IL8 (anti-IL-8 monoclonal antibody)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED